Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Non-Current Liabilities (2021 - 2025)

Agios Pharmaceuticals' Total Non-Current Liabilities history spans 8 years, with the latest figure at $104.0 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 14.29% year-over-year to $104.0 million; the TTM value through Dec 2025 reached $104.0 million, down 14.29%, while the annual FY2025 figure was $104.0 million, 14.29% down from the prior year.
  • Total Non-Current Liabilities reached $104.0 million in Q4 2025 per AGIO's latest filing, up from $101.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $164.0 million in Q3 2024 to a low of $88.1 million in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $119.4 million, with a median of $119.5 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 37.49% in 2024, then plummeted 38.23% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $145.8 million in 2021, then dropped by 7.64% to $134.6 million in 2022, then fell by 7.19% to $124.9 million in 2023, then dropped by 2.87% to $121.4 million in 2024, then dropped by 14.29% to $104.0 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Total Non-Current Liabilities are $104.0 million (Q4 2025), $101.3 million (Q3 2025), and $101.6 million (Q2 2025).